Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Yahoo Finance·2026-02-25 13:30
Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Context Achieved record 2025 revenues of $719 million, successfully transitioning the business model following the loss of exclusivity for legacy products Trokendi XR and Oxtellar XR. Growth was primarily driven by a 40% revenue increase across four key products: Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO, which now represent 76% of total revenues. Successfully integrated the Sage Therapeutics acqui ...